A survey conducted among migraineurs in Genova, Italy, found that during the coronavirus disease 2019 (COVID-19) quarantine, patients experienced fewer migraine attacks and less pain but exhibited moderate levels of depression correlated to migraine burden.
A survey conducted among migraineurs in Genova, Italy, found that during the coronavirus disease 2019 (COVID-19) quarantine, patients experienced fewer migraine attacks and less pain but exhibited moderate levels of depression correlated to migraine burden. The findings were published in Neurological Sciences.
Italy was one of the earliest countries to experience widespread public disruptions and hospitalizations due to COVID-19. On February 23, small towns hit by the outbreak were first put under quarantine, and on March 10, the entire nation was placed on lockdown. Travel bans and mandatory stay-at-home orders were enforced through May 3.
Researchers point out that quarantine is a well-known risk factor for psychological and psychiatric disturbances. To assess the impact of lockdown on migraine in terms of migraine burden, and on associated anxiety and depressive symptoms, participants recruited from a headache clinic completed a series of surveys and evaluations.
Between January 1 and March 9, 2020, a retrospective consecutive cohort of patients admitted to a headache clinic was recruited to the study. Only those completing follow-up visits were considered for the study. In total, 49 individuals were included, 79.59% of whom were female, with a mean (SD) age of 46.24 (15.04) years. In addition, 20.4% of the cohort exhibited migraine with aura.
All participants underwent telephonic clinical evaluations, personal interviews, and evaluation of migraine severity via the Global Assessment of Migraine Severity (GAMS) and Visual Analogue Scale (VAS). Depression and anxiety were measured by the Beck depression inventory (BDI) and Zung Self-Rating Anxiety Scale (SAS), respectively.
“Paired sample t test was performed to evaluate the changes in the value of migraine score from the 2 months immediately before lockdown (from January 1st to March 9th) to the 2 months of quarantine (from March 10th to May 3rd),” the authors wrote.
The study yielded the following results:
Although the analysis found mild to moderate levels of depression and mild levels of anxiety during the 2-month period of quarantine, due to lack of data, researchers were unable to compare the information with the period before lockdown.
Authors hypothesized that the prolonged period of time spent at home may have reduced outside stressors coming from work and social activity, thus reducing triggers of migraine attacks. Furthermore, presence of anxiety and depression could be related to the specific cause of lockdown: the COVID-19 pandemic. However, data did show “an interaction between depression and migraine burden, with better course of migraine in less depressed subjects.”
The retrospective design and lack of data on psychiatric comorbidities prior to quarantine pose limitations to the study, along with a relatively small sample size. The findings may not be generalizable to the wider population with migraine.
Reference
Parodi IC, Poeta MG, Assini A, et al. Impact of quarantine due to COVID infection on migraine: a survey in Genova, Italy. Neurol Sci. Published online July 1, 2020. doi:10.1007/s10072-020-04543-x
Prior Authorization Requirements for Calcitonin Gene-Related Peptide Antagonists
April 20th 2023This quantitative and qualitative analysis highlights differences in prior authorization requirements for migraine drugs from nearly 50 managed care organizations and summarizes broad types of criteria used.
Read More
Update on Migraine Patient Care Challenges During the Pandemic
October 5th 2021Migraines plague some 35 million Americans, the majority of them women in their 30s and 40s, and disabling pain and symptoms are linked to lost productivity at work, school, and home. On this episode of Managed Care Cast, we bring you an excerpt of an interview with a headache specialist about the extra challenges for patients and providers during the pandemic.
Listen
CGRP Inhibitors: A Promising New Class of Drugs for Migraine
November 14th 2018This fall, The American Journal of Managed Care® convened a panel of experts on migraine to discuss calcitonin gene-related peptide (CGRP) inhibitors, an emerging therapy for the condition, which affects 39 million people in the United States.
Listen